IN
INNMF.US Amplia Therapeutics Limited
- Market cap
- USD 27.7M
- P/E
- -
- P/B
- 1.02x
- ROE
- -19.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is INNMF.US undervalued?
Graham numberThe Graham number of Amplia Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Amplia Therapeutics Limited fundamental analysis
No fundamental analysis for Amplia Therapeutics Limited yet.
Amplia Therapeutics Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Amplia Therapeutics Limited
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immuno…
Full company profileAmplia Therapeutics Limited financial statements
Amplia Therapeutics Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.80M | 580K | 50.5K | 34.2K | 1.53M | 1.98M | 1.19M | 4.45M | 3.78M | - |
| Gross Profit | 1.76M | 560K | 48.9K | 33.4K | 1.53M | 1.98M | 1.12M | 4.01M | 3.57M | -92.3K |
| Operating Income | -8.97M | -4.83M | -1.93M | -2.26M | -2.28M | -3.64M | -6.19M | -4.42M | -6.52M | -13.2M |
| EBITDA | -7.10M | -4.30M | -1.92M | -2.25M | -2.34M | -3.64M | -7.26M | -4.48M | -6.71M | -13.1M |
| Net Income | -7.08M | -4.30M | -1.87M | -2.22M | -2.28M | -3.64M | -6.24M | -4.50M | -6.57M | -7.72M |
| EPS | -0.30 | -0.17 | -0.04 | -0.04 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 7.54M | 2.64M | 9.19M | 9.12M | 10.9M | 24.5M | 18.7M | 14.8M | 22.9M | 41.5M |
| Total Liabilities | 908K | 279K | 527K | 511K | 539K | 2.64M | 2.85M | 3.43M | 1.91M | 1.97M |
| Shareholders' Equity | 6.63M | 2.36M | 8.66M | 8.61M | 10.3M | 21.8M | 15.8M | 11.4M | 21.0M | 39.5M |
| Cash & Short-term Investments | 5.76M | 2.23M | 1.24M | 1.11M | 1.85M | 14.6M | 9.26M | 3.39M | 10.9M | 27.9M |
| Total Debt | 10.3K | 10.6K | 10.6K | - | - | 2.10M | 2.27M | 1.59M | 13.9K | 342K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -6.16M | -3.55M | -987K | -2.09M | -2.92M | -4.40M | -5.29M | -5.13M | -6.89M | -8.75M |
| Capital Expenditure | 46.5K | 4.42K | 3.19K | 5.35K | 5.35K | 14.4K | 17.6K | 2.23K | 2.07K | 33.4K |
| Free Cash Flow | -6.21M | -3.55M | -991K | -2.09M | -2.92M | -4.42M | -5.31M | -5.13M | -6.89M | -8.78M |
| Ratios | ||||||||||
| ROE | -106.7% | -181.8% | -21.6% | -25.8% | -22.1% | -16.7% | -39.4% | -39.4% | -31.3% | -19.5% |
| ROA | -93.9% | -162.6% | -20.3% | -24.3% | -21.0% | -14.9% | -33.4% | -30.3% | -28.7% | -18.6% |
| Net Profit Margin | -393.5% | -740.6% | -3,704.8% | -6,484.6% | -148.8% | -183.7% | -524.8% | -101.1% | -173.7% | - |
| Debt to Equity | 0.00x | 0.00x | 0.00x | - | - | 0.10x | 0.14x | 0.14x | 0.00x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Amplia Therapeutics Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 2.10M | 0.01 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 257:250 on Apr 23, 2024.
Who owns Amplia Therapeutics Limited
- Insiders 9.56%
- Institutions 23.07%
- Public & others 67.36%
- Shares outstanding 513M
- Free float 414M
Amplia Therapeutics Limited company profile
- Company name
- Amplia Therapeutics Limited
- Ticker
- INNMF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- March
- Address
- 90 William Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9123 1140
- Website
- ampliatx.com
About Amplia Therapeutics Limited
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Amplia Therapeutics Limited management
5- Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D.CEO, MD & Director · born 1965
- Mr. Hamish George B.Com., C.A.Chief Financial Officer
- Ms. Rhiannon Jones B.Sc., Ph.D.Chief Operating Officer
- Dr. Jason Lickliter MBBSChief Medical Officer
- Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., MAICDCompany Secretary · born 1960